A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

This study is testing a medication called talazoparib to see how well it works for people with advanced cancers that have specific genetic changes. These changes affect how a tumor repairs its own DNA, and this drug works by blocking that repair process to help stop the cancer from growing.

This trial is for adults with advanced cancers—including breast, prostate, stomach, ovarian, or pancreatic—that have specific gene mutations, such as BRCA1 or BRCA2. Patients must have had their cancer worsen after standard treatments or be in a situation where those standard options are no longer effective.

Participants will take the medication talazoparib and undergo regular health monitoring, which includes blood tests, tissue samples, and imaging scans like CTs or MRIs to track how the body is responding. The goal is to see if this targeted therapy can effectively stop cancer cells from fixing themselves.

This study currently takes place in Gainesville, Florida, and Bethesda, Maryland. Please note that the study is active but is not currently recruiting new patients.